Flibanserin for Treating Hypoactive Sexual Desire Disorder.

Area of Science:

• Pharmacology
• Neuroscience
• Women's Health

Background:

• Male sexual dysfunction treatments are more advanced than those for female sexual dysfunction.
• Existing male treatments like sildenafil citrate (Viagra) and tadalafil (Cialis) primarily target vascular mechanisms.
• Female sexual dysfunction treatments have historically lagged due to various factors.

Purpose of the Study:

• To introduce flibanserin, a novel pharmacological agent, to sexologists and menopausal medicine physicians.
• To provide awareness of flibanserin as a treatment option for hypoactive sexual desire disorder (HSDD) in premenopausal women.
• To facilitate the safe and effective use of flibanserin for eligible female patients.

Main Methods:

• Review of flibanserin's mechanism of action, distinguishing it from vascular-acting agents.
• Discussion of the FDA approval of flibanserin for HSDD in premenopausal women (2015).
• Anticipation of flibanserin's release in South Korea.

Main Results:

• Flibanserin is understood to exert its effects through central nervous system pathways, targeting brain activity.
• Flibanserin received U.S. Food and Drug Administration (FDA) approval in 2015 for treating HSDD in premenopausal women.
• The drug is slated for release in South Korea, expanding access to this treatment.

Conclusions:

• Flibanserin represents a significant advancement in the treatment of female sexual dysfunction, specifically HSDD.
• Physicians are encouraged to consider flibanserin for appropriate patients, acknowledging its distinct neuropharmacological profile.
• This article serves as an informational resource to promote the appropriate clinical application of flibanserin.